Israel - English - Ministry of Health

abbvie biopharmaceuticals ltd, israel - venetoclax - film coated tablets - venetoclax 50 mg - venetoclax - chronic lymphocytic leukemia/small lymphocytic lymphomavenclexta in combination with rituximab or as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll), who have received at least one prior therapy.venclexta in combination with obinutuzumab is indicated for the treatment of patients with previously untreated chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll).acute myeloid leukemiavenclexta in combination with a hypomethylating agent or in combination with low dose cytarabine is indicated for newly diagnosed patients with acute myeloid leukemia (aml) who are ineligible for intensive chemotherapy.

Israel - English - Ministry of Health

abbvie biopharmaceuticals ltd, israel - venetoclax - film coated tablets - venetoclax 10 mg - venetoclax - chronic lymphocytic leukemia/small lymphocytic lymphoma :venclexta in combination with rituximab or as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll), who have received at least one prior therapy.venclexta in combination with obinutuzumab is indicated for the treatment of patients with previously untreated chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll).acute myeloid leukemia :venclexta in combination with a hypomethylating agent or in combination with low dose cytarabine is indicated for newly diagnosed patients with acute myeloid leukemia (aml) who are ineligible for intensive chemotherapy.

Israel - English - Ministry of Health

abbvie biopharmaceuticals ltd, israel - venetoclax - film coated tablets - venetoclax 10 mg - venetoclax - chronic lymphocytic leukemia/small lymphocytic lymphoma :venclexta in combination with rituximab or as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll), who have received at least one prior therapy.venclexta in combination with obinutuzumab is indicated for the treatment of patients with previously untreated chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll).acute myeloid leukemia :venclexta in combination with a hypomethylating agent or in combination with low dose cytarabine is indicated for newly diagnosed patients with acute myeloid leukemia (aml) who are ineligible for intensive chemotherapy.

Israel - English - Ministry of Health

abbvie biopharmaceuticals ltd, israel - venetoclax - film coated tablets - venetoclax 100 mg - venetoclax - chronic lymphocytic leukemia/small lymphocytic lymphoma :venclexta in combination with rituximab or as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll), who have received at least one prior therapy.venclexta in combination with obinutuzumab is indicated for the treatment of patients with previously untreated chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll).acute myeloid leukemia :venclexta in combination with a hypomethylating agent or in combination with low dose cytarabine is indicated for newly diagnosed patients with acute myeloid leukemia (aml) who are ineligible for intensive chemotherapy.

Israel - English - Ministry of Health

abbvie biopharmaceuticals ltd, israel - venetoclax - film coated tablets - venetoclax 100 mg - venetoclax - chronic lymphocytic leukemia/small lymphocytic lymphoma :venclexta in combination with rituximab or as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll), who have received at least one prior therapy.venclexta in combination with obinutuzumab is indicated for the treatment of patients with previously untreated chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll).acute myeloid leukemia :venclexta in combination with a hypomethylating agent or in combination with low dose cytarabine is indicated for newly diagnosed patients with acute myeloid leukemia (aml) who are ineligible for intensive chemotherapy.

Israel - English - Ministry of Health

abbvie biopharmaceuticals ltd, israel - venetoclax - film coated tablets - venetoclax 50 mg - venetoclax - chronic lymphocytic leukemia/small lymphocytic lymphoma :venclexta in combination with rituximab or as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll), who have received at least one prior therapy.venclexta in combination with obinutuzumab is indicated for the treatment of patients with previously untreated chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll).acute myeloid leukemia :venclexta in combination with a hypomethylating agent or in combination with low dose cytarabine is indicated for newly diagnosed patients with acute myeloid leukemia (aml) who are ineligible for intensive chemotherapy.

Israel - English - Ministry of Health

abbvie biopharmaceuticals ltd, israel - venetoclax - film coated tablets - venetoclax 50 mg - venetoclax - chronic lymphocytic leukemia/small lymphocytic lymphoma :venclexta in combination with rituximab or as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll), who have received at least one prior therapy.venclexta in combination with obinutuzumab is indicated for the treatment of patients with previously untreated chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll).acute myeloid leukemia :venclexta in combination with a hypomethylating agent or in combination with low dose cytarabine is indicated for newly diagnosed patients with acute myeloid leukemia (aml) who are ineligible for intensive chemotherapy.

Singapore - English - HSA (Health Sciences Authority)

hope technik pte ltd - general hospital - tas2000 is a temperature assessment system that is used to quickly check if the person is in the non-febrile range or febrile range. if the person is in the febrile range, he needs to use another thermometer to check his temperature.

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - imatinib mesilate 119.47mg equivalent to imatinib 100 mg;   - capsule - 100 mg - active: imatinib mesilate 119.47mg equivalent to imatinib 100 mg   excipient: crospovidone gelatin iron oxide red iron oxide yellow lactose monohydrate magnesium stearate titanium dioxide - treatment of adult and paediatric patients with newly diagnosed philadelphia chromosome positive chronic myeloid leukaemia (ph+cml). treatment of adult and paediatic patients with ph+cml in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - imatinib mesilate 477.88mg equivalent to imatinib 400 mg;   - capsule - 400 mg - active: imatinib mesilate 477.88mg equivalent to imatinib 400 mg   excipient: crospovidone gelatin iron oxide black iron oxide red iron oxide yellow lactose monohydrate magnesium stearate titanium dioxide - treatment of adult and paediatric patients with newly diagnosed philadelphia chromosome positive chronic myeloid leukaemia (ph+cml). treatment of adult and paediatic patients with ph+cml in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy.